

Remarks

Reconsideration and withdrawal of the rejections of the claims, in view of the amendments and remarks herein, is respectfully requested. Claim 1 is amended, and claim 4 is canceled. Claims 1-3 and 5-8 are pending. The amendments are intended to further prosecution and not intended to concede to the correctness of the Examiner's position or to prejudice the prosecution of the claims prior to amendment, which claims are present in a continuation of the present application.

The amendments to the title and Abstract address items 3 and 4 in the Office Action.

Amended claim 1 is supported by originally-filed claims 1 and 4 and at page 4, line 11 of the specification.

The 35 U.S.C. § 112 Rejections

The Examiner rejected claims 1 and 5-8 under 35 U.S.C. § 112, first paragraph, as the specification does not reasonably convey to one skilled in the art that the inventor(s) had possession of the claimed invention at the time the application was filed. The amendment to claim 1, to recite "vertebrate", renders this rejection moot.

The Examiner also rejected claims 1 and 5-8 under 35 U.S.C. § 112, first paragraph, as the specification, while being enabling for the vertebrate myostatin, allegedly does not reasonably provide enablement for any full length myostatin. This rejection, as it may be maintained with respect to the pending claims, is respectfully traversed.

The specification discloses that the invention includes an immunogen such as a full length (mature form of) myostatin (page 4, lines 11-13). The specification also discloses that the sequence of myostatins from a variety of species was known prior to Applicant's effective filing date (page 18, lines 14-19 of the specification, see also Figure 1C and column 2, lines 17-20 in U.S. Patent No. 6,369,201, a reference cited against the claims under 35 U.S.C. §§ 102(e) and 103(a)). It is further disclosed that myostatin is generally composed of a secretory sequence (residues 1-262), a proteolytic processing site (residues 263-266), and a functional domain (residues 267-375) (page 17, lines 8-11). Moreover, the conserved nature of myostatin sequences was recognizable (see, e.g., Figure 1C of U.S. Patent No. 6,369,201).

Example 1 of the specification discloses that a myostatin fusion protein comprising the mature form of turkey myostatin (109 residues corresponding to the functional domain mentioned above; Figure 1 shows the sequence of the mature form of turkey myostatin) was prepared and employed as an immunogen.

Thus, Applicant's specification provides an enabling disclosure of the mature form of vertebrate myostatin. Accordingly, withdrawal of the § 112(1) rejections is respectfully requested.

The 35 U.S.C. § 102(e) and § 103(a) Rejections

The Examiner rejected claims 1-4 and 6-8 under 35 U.S.C. § 102(e) as being anticipated by Barker et al. (U.S. Patent No. 6,369,201). The Examiner also rejected claims 1-8 under 35 U.S.C. § 103(a) as being unpatentable over Barker et al. in view of Harris et al. (Micron, 30, 597 (1999)). These rejections are respectfully traversed.

Barker et al. generally disclose myostatin peptide immunogens, myostatin multimers and myostatin immunoconjugates capable of eliciting an immune response in a vertebrate subject (abstract) and useful to treat conditions that cause degeneration or wasting of muscle, increase body weight, reduce body fat content, increase mammary gland tissue, increase lactation, increase appetite or feed uptake, or increase life span (column 2, lines 61-64 and column 4, lines 25-35). It is disclosed that a myostatin peptide consists of about 3 to about 100 amino acids and comprises at least one epitope of myostatin, a myostatin multimer comprises two or more myostatin immunogens, and a myostatin immunoconjugate comprises at least one myostatin peptide or multimer linked to an immunological carrier (column 3, lines 78-50 and column 4, lines 1-4). Myostatin peptides or polypeptides of various lengths are described: residues 1-350, 1-275, 25-300, 50-325, 75-350, 45-376 or 235-376, e.g., of SEQ ID NOs:27-36; residues 3-15 of SEQ ID NO:6; residues 3-18 of SEQ ID NO:4, residues 3-16 of SEQ ID NO:10; residues 3-17 of SEQ ID NO:8; residues 3-18 of SEQ ID NO:20 or SEQ ID NO:22; residues 3-22 of SEQ ID NO:12 or SEQ ID NO:16; and residues 3-25 of SEQ ID NO:14 (column 3, lines 12-57). The active region of myostatin is disclosed as spanning amino acids 264-375 (column 5, lines 46-47).

A myostatin immunogen is defined as a polypeptide, recombinant or chemically

synthesized, which elicits an immune response without an associated immunological carrier as well as polypeptides capable of being rendered immunogenic or more immunogenic with a carrier molecule, adjuvant or immunostimulant (column 6, lines 13-21 and column 7, lines 1-5). An immunological carrier is disclosed as any molecule which, when associated with a myostatin immunogen of interest, imparts immunogenicity to that molecule, or enhances the immunogenicity of that molecule. Keyhole limpet hemocyanin (KLH) is among 12 specified immunological carriers (column 9, lines 22-33 and column 15, lines 17-29).

Example 1 of Barker et al. describes ten myostatin oligonucleotides to be employed in constructs individually as well as together in a reconstructed myostatin sequence (MYOS 1 encodes residues 263-278 of SEQ ID NO:2; MYOS 3 encodes residues 279-291 of SEQ ID NO:2; MYOS 5 encodes residues 290-304 of SEQ ID NO:2; MYOS 7 encodes residues 302-315 of SEQ ID NO:2; MYOS 9 encodes residues 314-333 of SEQ ID NO:2; MYOS 11 encodes residues 336-358 of SEQ ID NO:2; MYOS 13 encodes residues 356-375 of SEQ ID NO:2; MYOS 15 encodes residues 28-44 of SEQ ID NO:2; MYOS 17 encodes residues 235-250 of SEQ ID NO:2; and MYOS 19 encodes residues 250-280 of SEQ ID NO:2). Each oligonucleotide also includes sequences at the 5' end encoding Gly-Ser and at the 3' end encoding Arg-Ser. MYOS oligonucleotides complementary to MYOS 3, 5, 7, 9, 11, 13, 15, 17, and 19 are MYOS 4, 6, 8, 10, 12, 14, 16, 18, and 20, respectively. The reconstructed myostatin sequence, which combines MYOS 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, and 14, is disclosed as substantially corresponding to the active portion of myostatin, and its use "assures proper three-dimensional structure to elicit an effective immune response" (column 27, lines 22-26).

Each construct was introduced into a vector which fused the oligonucleotide or reconstructed myostatin sequence to DNA encoding leukotoxin carrier protein (LKT) (Example 2). pCB317 is a vector which contains a single copy of the reconstructed myostatin sequence fused to LKT, a sequence which encodes three sets of two amino acid linkers inserted at positions 55-60, 136-144, 241-246 and 367-372 in the encoded polypeptide (column 30, lines 27-32).

Plasmids with each construct were introduced to *E. coli* and recombinant fusion peptides or polypeptides isolated (Example 4). Example 5 discloses that the recombinant fusion peptide

or polypeptide immunogens were injected into CD1 Swiss mice at day 0 (3-4 weeks of age), day 28 and day 56, and body weights determined at day 0, 84 and 98 (Table 2). Body weights in treatment group 13 (MYOS 19; myostatin residues 250-280) are disclosed as significantly different from the body weights in all three control groups, and the body weights in treatment group 12 (MYOS 17; myostatin residues 235-250) and group 6 (MYOS 5; myostatin residues 290-304) are disclosed as significantly different from 2/3 control groups. Nevertheless, the overall results for the seven peptide immunogens having only sequences in the active region (peptides corresponding to MYOS 1, 3, 5, 7, 9, 11, and 13) were not so different than the results for peptide immunogens having sequences only in the non-active region or overlapping with the active region (peptides corresponding to MYOS 15, 17 and 19). Notably, the body weights for the group treated with a reconstituted myostatin immunoconjugate were not significantly different from the body weights in 3/3 control groups, i.e., the reconstituted myostatin immunoconjugate did not elicit an immune response.

Thus, Barker et al. do not teach or suggest Applicant's immunoconjugate.

Harris et al. review the biochemistry of KLH and its use as a generalized vaccine component. Harris et al. note that there is a large volume of evidence indicating the potential of a KLH-conjugate for the generation of a specific response to small molecular mass haptens (page 615). It is also disclosed that KLH-peptide vaccines were found to be protective or capable of eliciting neutralizing antibodies (page 615).

Nevertheless, Harris et al. do not cure the deficiencies in Barker et al. as neither reference discloses or suggest a myostatin immunoconjugate comprising the mature form of vertebrate myostatin linked to a carrier.

Further, as 1) only certain myostatin peptides, but not a myostatin immunogen comprising a plurality of myostatin peptide sequences, were effective to significantly increase body weight and 2) it was well known that it can be quite difficult to raise antibodies in an animal to a highly conserved protein (see Gouli et al., Biochem. Internatl., 21, 685 (1990), a copy of which is enclosed herewith) or to "self" antigens in general due to clonal exclusion during development, the art worker would not be motivated to prepare a myostatin immunoconjugate other than a peptide immunoconjugate corresponding to myostatin residues 235-250, 250-280 or 290-304.

Thus, withdrawal of the § 102(e) and § 103(a) rejections is respectfully requested.

Conclusion

Applicant respectfully submits that the claims are in condition for allowance and notification to that effect is earnestly requested. The Examiner is invited to telephone Applicant's attorney (612-373-6959) to facilitate prosecution of this application.


If necessary, please charge any additional fees or credit overpayment to Deposit Account No. 19-0743.

Respectfully submitted,

MOHAMED E. EL HALAWANI ET AL.,

By their Representatives,

SCHWEGMAN, LUNDBERG, WOESSNER & KLUTH, P.A.
P.O. Box 2938
Minneapolis, MN 55402
(612) 373-6959


Date September 6, 2002 By 
Janet E. Embretson
Reg. No. 39,665

CERTIFICATE UNDER 37 CFR 1.8: The undersigned hereby certifies that this correspondence is being deposited with the United States Postal Service with sufficient postage as first class mail, in an envelope addressed to: Commissioner of Patents, Washington, D.C. 20231, on this 6th day of September, 2002.

Name

Dawn M. Poole

Signature



CLEAN VERSION OF ABSTRACT

USE OF PASSIVE MYOSTATIN IMMUNIZATION

Applicant: Mohamed E. El Halawani et al.

Serial No.: 09/754,826

Abstract of the Disclosure

02
A myostatin immunoconjugate and its use to alter the phenotype of animals, e.g., avians, is provided.

CLEAN VERSION OF THE TITLE

USE OF PASSIVE MYOSTATIN IMMUNIZATION

Applicant: Mohamed E. El Halawani et al.

Serial No.: 09/754,826

MYOSTATIN IMMUNOCONJUGATE

Clean Version of Pending Claims

USE OF PASSIVE MYOSTATIN IMMUNIZATION

Applicant: Mohamed E. El Halawani et al.

Serial No.: 09/754,826

1. A myostatin immunoconjugate and its use to alter the phenotype of animals, e.g., avians, is provided.

2. The immunoconjugate of claim 1 which comprises an avian myostatin polypeptide.

3. The immunoconjugate of claim 2 which comprises a turkey myostatin polypeptide comprising SEQ ID NO:2.

5. The immunoconjugate of claim 1 wherein the carrier is keyhole limpet hemocyanin.

6. The immunoconjugate of claim 1 which comprises a fusion polypeptide.

7. A vaccine or immunogenic composition comprising the immunoconjugate of claim 1.

8. The vaccine or immunogenic composition of claim 7 which comprises a pharmaceutically acceptable excipient.